Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Expands By 200.0%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 1,500 shares, a growth of 200.0% from the September 30th total of 500 shares. Based on an average trading volume of 1,300 shares, the days-to-cover ratio is presently 1.2 days.

Clinuvel Pharmaceuticals Stock Performance

Shares of OTCMKTS CLVLY opened at $9.32 on Friday. The firm has a 50 day moving average price of $9.65 and a two-hundred day moving average price of $9.82. Clinuvel Pharmaceuticals has a 52-week low of $8.42 and a 52-week high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were issued a $0.0299 dividend. This is an increase from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date of this dividend was Monday, September 9th.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).